KLRS

8.26

5.71% -0.50

Dopo l'orario di chiusura: 8.30 0.04 +0.48%

Kalaris Therapeutics Inc (KLRS)

Panoramica Notizia Cronologia dei prezzi Forum Previsione

Precedente Chiudi:

$8.76

Aprire:

$8.82

Volume 24 ore:

45,258

Relative Volume:

0.28

Capitalizzazione di mercato:

$154.48M

Reddito:

Utile/perdita netta:

Rapporto P/E:

EPS:

Flusso di cassa netto:

1 W Prestazione:

-2.13%

1M Prestazione:

+34.09%

6M Prestazione:

+220.16%

1 anno Prestazione:

+0.00%

Intervallo 1D:

$8.26

$8.96

Intervallo di 1 settimana:

$7.915

$9.0907

Portata 52W:

$2.14

$12.50

Kalaris Therapeutics Inc Stock (KLRS) Company Profile

Nome

Kalaris Therapeutics Inc

Settore

Healthcare (1113)

Industria

Biotechnology (621)

Telefono

650-249-2727

Indirizzo

400 CONNELL DRIVE, BERKELEY HEIGHTS

Dipendente

Cinguettio

Prossima data di guadagno

Ultimi documenti SEC

KLRS's Discussions on Twitter

Confronta KLRS con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
KLRS Kalaris Therapeutics Inc	8.26	163.83M	0	0	0	0.00
VRTX Vertex Pharmaceuticals Inc	469.68	122.84B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	801.01	85.37B	14.25B	4.58B	3.88B	41.77
ALNY Alnylam Pharmaceuticals Inc	399.40	55.82B	3.21B	43.57M	221.36M	0.2405
ARGX Argen X Se Adr	795.57	50.67B	3.06B	1.28B	447.35M	19.67
INSM Insmed Inc	170.27	37.54B	447.02M	-1.18B	-906.14M	-6.1812

Kalaris Therapeutics Inc Stock (KLRS) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2025-12-23	Iniziato	Chardan Capital Markets	Buy
2025-11-03	Iniziato	Citizens JMP	Mkt Outperform
2025-09-03	Iniziato	Raymond James	Strong Buy
2025-07-23	Ripresa	Piper Sandler	Neutral
2025-05-07	Iniziato	Leerink Partners	Outperform
2025-04-08	Iniziato	William Blair	Outperform

Mostra tutto

Kalaris Therapeutics Inc Borsa (KLRS) Ultime notizie

Jan 08, 2026

How Kalaris Therapeutics Inc. stock responds to policy changesQuarterly Profit Review & Safe Capital Investment Plans - ulpravda.ru

Jan 08, 2026

Why retail investors pile into Kalaris Therapeutics Inc. stockJuly 2025 Trade Ideas & Long-Term Investment Growth Plans - ulpravda.ru

Jan 08, 2026

Is Kalaris Therapeutics Inc. stock a defensive play in 2025Treasury Yields & Reliable Volume Spike Trade Alerts - ulpravda.ru

Jan 08, 2026

Jan 07, 2026

Kalaris Therapeutics raises $50M privately - MSN

Jan 07, 2026

Dec 31, 2025

Short Interest in Kalaris Therapeutics Inc. (NASDAQ:KLRS) Expands By 26.1% - MarketBeat

Dec 31, 2025

Dec 26, 2025

Analysts’ Weekly Ratings Updates for Kalaris Therapeutics (KLRS) - Defense World

Dec 26, 2025

Dec 25, 2025

Chardan Capital Initiates Coverage on Kalaris Therapeutics (NASDAQ:KLRS) - Defense World

Dec 25, 2025

Dec 24, 2025

Kalaris Therapeutics announces initial data from TH103 trial - MSN

Dec 24, 2025

Chardan Capital Upgrades Kalaris Therapeutics (NASDAQ:KLRS) to Strong-Buy - MarketBeat

Dec 24, 2025

Dec 23, 2025

Chardan Capital Initiates Coverage of Kalaris Therapeutics (KLRS) with Buy Recommendation - Nasdaq

Dec 23, 2025

Chardan Initiates Kalaris Therapeutics at Buy With $19 Price Target - marketscreener.com

Dec 23, 2025

Chardan Capital Markets initiates coverage on Kalaris stock with Buy rating - Investing.com Nigeria

Dec 23, 2025

Kalaris Therapeutics Inc. (NASDAQ:KLRS) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat

Dec 23, 2025

Kalaris Therapeutics Inc. (NASDAQ:KLRS) Given Average Rating of “Moderate Buy” by Analysts - Defense World

Dec 23, 2025

Dec 21, 2025

Why Kalaris Therapeutics Inc. stock is rated strong buyJuly 2025 Chart Watch & Real-Time Volume Triggers - Улправда

Dec 21, 2025

Dec 20, 2025

KLRS Kalaris Therapeutics Inc +8.76%eToro - eToro

Dec 20, 2025

Kalaris Therapeutics (NASDAQ:KLRS) Upgraded by Wall Street Zen to "Hold" Rating - MarketBeat

Dec 20, 2025

Kalaris Therapeutics (NASDAQ:KLRS) Upgraded by Wall Street Zen to “Hold” Rating - Defense World

Dec 20, 2025

Why Kalaris Therapeutics Inc. stock is popular among millennialsJuly 2025 WrapUp & AI Powered Market Entry Strategies - Улправда

Dec 20, 2025

Dec 19, 2025

Will Kalaris Therapeutics Inc. stock deliver long term returnsJuly 2025 Momentum & Comprehensive Market Scan Reports - Улправда

Dec 19, 2025

Kalaris Therapeutics: Phase 1a Data De-Risks The Path To 2026 Catalysts (KLRS) - Seeking Alpha

Dec 19, 2025

Targets Report: Why Kalaris Therapeutics Inc. stock is popular among millennialsTrade Performance Summary & Smart Swing Trading Alerts - Улправда

Dec 19, 2025

Latham & Watkins Advises on Kalaris Therapeutics’ US$50 Million Private Placement - Legal Desire Media and Insights

Dec 19, 2025

Fundamentals Check: Will Kalaris Therapeutics Inc. stock outperform growth indexesJuly 2025 Reactions & Reliable Momentum Entry Alerts - Улправда

Dec 19, 2025

Dec 18, 2025

Kalaris Therapeutics: TH103 Trial Success And $50M Raise Set Stage For Growth (KLRS) - Seeking Alpha

Dec 18, 2025

Kalaris stock price target raised to $26 at Citizens on TH103 data - Investing.com Canada

Dec 18, 2025

Kalaris Therapeutics Announces Oversubscribed $50 Million Financing - TipRanks

Dec 18, 2025

Kalaris Therapeutics Signs Multiple Material Agreements - TradingView — Track All Markets

Dec 18, 2025

Kalaris Therapeutics (NASDAQ: KLRS) lines up $50M private placement - Stock Titan

Dec 18, 2025

Kalaris Rises On Positive Early Data From Neovascular AMD Trial And $50Mln Financing Boost - Nasdaq

Dec 18, 2025

Kalaris Therapeutics Reports Positive Initial Phase 1a Data for TH103 in Treatment-Naïve Neovascular AMD - The Manila Times

Dec 18, 2025

Kalaris reports positive early data for TH103 in AMD treatment By Investing.com - Investing.com Australia

Dec 18, 2025

Dec 17, 2025

Aspen Aerogels Announces Amendment to MidCap Credit Facility - The Manila Times

Dec 17, 2025

Vine Hill Capital Investment Corp. II Announces Pricing of Upsized $200 Million Initial Public Offering - The Manila Times

Dec 17, 2025

Future Mineral Announces Options Grant - The Manila Times

Dec 17, 2025

LACAHSA Board Approves $11.4M for Emergency Rental Assistance Funding, Bringing Total Measure A Prevention Investments to $29.5M in 2025 - The Manila Times

Dec 17, 2025

Kalaris Therapeutics Announces Oversubscribed $50.0 Million Private Placement - The Manila Times

Dec 17, 2025

Biotech developing eye disease drug secures $50M to fund trials to 2027 - Stock Titan

Dec 17, 2025

Kalaris Posts Positive Results from Macular Degeneration Drug Trial - marketscreener.com

Dec 17, 2025

Kalaris Therapeutics Reports Initial Positive Phase 1a Data for TH103 in nAMD - TradingView — Track All Markets

Dec 17, 2025

[8-K] Kalaris Therapeutics, Inc. Reports Material Event | KLRS SEC FilingForm 8-K - Stock Titan

Dec 17, 2025

Kalaris reports positive early data for TH103 in AMD treatment - Investing.com India

Dec 17, 2025

Kalaris Therapeutics reports positive initial Phase 1a data for TH103 - marketscreener.com

Dec 17, 2025

Single eye injection boosts vision in early test for macular degeneration - Stock Titan

Dec 17, 2025

Dec 16, 2025

Kalaris Therapeutics, Inc. announced that it expects to receive $49.99992 million in funding - marketscreener.com

Dec 16, 2025

Gold hits 5 week high – More gains aheadSector-Based Investing & Free Phenomenal Trading Returns - Bollywood Helpline

Dec 16, 2025

Dec 15, 2025

Kalaris Therapeutics Earnings Notes - Trefis

Dec 15, 2025

Dec 13, 2025

Kalaris Therapeutics, Inc.'s (NASDAQ:KLRS) Biggest Owners Are Private Equity Firms Who Got Richer After Stock Soared 51% Last Week - 富途牛牛

Dec 13, 2025

Dec 10, 2025

Kalaris Therapeutics Inc Stock Analysis and ForecastPrice Volatility Patterns & Smarter Trades Backed by Machine Learning - earlytimes.in

Dec 10, 2025